← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Other blood glucose lowering drugs, excl. insulins
imeglimin
A10BX15
Forms & Strengths
- Oral tablets: 500 mg, 1000 mg
Adult Dosing
- 1000 mg orally twice daily with or without food
- Reduce dose in moderate to severe renal impairment (eGFR < 45 mL/min/1.73m²)
Pediatric Dosing
- Safety and efficacy not established in patients under 18 years of age
Indications
- Treatment of type 2 diabetes mellitus as monotherapy or as add-on therapy to other glucose-lowering agents
Mechanism of Action
- First-in-class glimin oral antidiabetic agent
- Increases glucose-stimulated insulin secretion by pancreatic beta cells
- Improves insulin sensitivity in skeletal muscle and liver
- Protects mitochondrial function and integrity in metabolic tissues
Contraindications
- Hypersensitivity to imeglimin or any excipient
- Type 1 diabetes mellitus
- Diabetic ketoacidosis
- Severe renal impairment requiring dialysis
Adverse Reactions
- Nasopharyngitis
- Upper respiratory tract infections
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
- Hypoglycemia (primarily when used with insulin or insulin secretagogues)
Drug Interactions
- Insulin and insulin secretagogues (sulfonylureas, glinides) increase the risk of hypoglycemia; dose reduction of these agents may be necessary
- Organic cation transporters (OCTs) inhibitors may theoretically affect pharmacokinetics, though clinical significance is low
Curated Content: Needs Vetting Before Put to Clinical Use